# Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-

> **NCT01166724** · PHASE3 · TERMINATED · sponsor: **The Cleveland Clinic** · enrollment: 12 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT01166724
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Collaborator stopped study
- **Last updated:** 2017-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166724, "Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01166724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*